Nir Lubezky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nir Lubezky has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Joseph M. Klausner
Surgical Department, Tel-Aviv Medical Center, Tel-Aviv, Israel
7 shared publicationsMenahem Ben-Haim
7 shared publicationsRichard Nakache
Unit of Organ Transplantation Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel‐Aviv University Tel‐Aviv Israel
7 shared publicationsGuy Lahat
4 shared publicationsJoseph Klausner
Tel Aviv Sourasky Medical Center
4 shared publicationsEli Brazowski
3 shared publications
Latest Publications
- 27 April 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (10) , 3971-3972
ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy
- 27 April 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (10) , 3971-3972
ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy
- 1 February 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (2) , 270
Reply letter to: Comments on “Solid pseudopapillary neoplasm of the pancreas: Management and long-term outcome”
- 1 February 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (2) , 270
Reply letter to: Comments on “Solid pseudopapillary neoplasm of the pancreas: Management and long-term outcome”
- 1 December 2016
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 14 (12) , 1254-1265
Adipose-Induced Retroperitoneal Soft Tissue Sarcoma Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells
Previous data demonstrated that high retroperitoneal visceral fat content increases retroperitoneal soft-tissue sarcoma (RSTS) local recurrence and patients' mortality. Most RSTS tumors initiate and recur within visceral fat. The objective of the current study was to evaluate potential paracrine effects of visceral fat on RSTS. A xenograft model was used to evaluate in vivo effects of human visceral fat on STS growth. Tissue explants were prepared from visceral fat, and their conditioned medium (CM) was utilized for various in vitro experiments designed to evaluate growth, survival, migration, and invasion of STS and endothelial cells. Visceral fat–secreted protumorigenic factors were identified by mass spectrometry. The in vivo experiments demonstrated a significant increase in STS tumor growth rate when SK-LMS-1 leiomyosarcoma cells were colocalized with human visceral fat compared with subcutaneous injection of cancer cells only. The in vitro model demonstrated that visceral fat CM increased STS cellular growth and reduced doxorubicin-induced apoptosis. Visceral fat also enhanced STS cellular migration and invasion. In addition, visceral fat CM significantly increased endothelial cell tube formation, suggesting its role as a proangiogenic factor in the STS tumor microenvironment (TME). Using a robust proteomic approach, liquid chromatography and tandem mass spectrometry resolved various molecules within the visceral fat CM, of which a subset was associated with protumorigenic biologic processes. These results suggest that visceral fat directly interacts with STS cells by secreting specific adipokines into the TME, thus augmenting STS tumor cell proliferation and invasiveness. Fat-induced STS molecular deregulations should be studied to identify new potential prognostic and therapeutic targets. Implications: Visceral fat induces protumorigenic effects, in STS, through various secreted factors that should be investigated to improve our understanding of adipose–cancer cell interactions. Mol Cancer Res; 14(12); 1254–65. ©2016 AACR.
- 1 December 2016
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 14 (12) , 1254-1265
Adipose-Induced Retroperitoneal Soft Tissue Sarcoma Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells
Previous data demonstrated that high retroperitoneal visceral fat content increases retroperitoneal soft-tissue sarcoma (RSTS) local recurrence and patients' mortality. Most RSTS tumors initiate and recur within visceral fat. The objective of the current study was to evaluate potential paracrine effects of visceral fat on RSTS. A xenograft model was used to evaluate in vivo effects of human visceral fat on STS growth. Tissue explants were prepared from visceral fat, and their conditioned medium (CM) was utilized for various in vitro experiments designed to evaluate growth, survival, migration, and invasion of STS and endothelial cells. Visceral fat–secreted protumorigenic factors were identified by mass spectrometry. The in vivo experiments demonstrated a significant increase in STS tumor growth rate when SK-LMS-1 leiomyosarcoma cells were colocalized with human visceral fat compared with subcutaneous injection of cancer cells only. The in vitro model demonstrated that visceral fat CM increased STS cellular growth and reduced doxorubicin-induced apoptosis. Visceral fat also enhanced STS cellular migration and invasion. In addition, visceral fat CM significantly increased endothelial cell tube formation, suggesting its role as a proangiogenic factor in the STS tumor microenvironment (TME). Using a robust proteomic approach, liquid chromatography and tandem mass spectrometry resolved various molecules within the visceral fat CM, of which a subset was associated with protumorigenic biologic processes. These results suggest that visceral fat directly interacts with STS cells by secreting specific adipokines into the TME, thus augmenting STS tumor cell proliferation and invasiveness. Fat-induced STS molecular deregulations should be studied to identify new potential prognostic and therapeutic targets. Implications: Visceral fat induces protumorigenic effects, in STS, through various secreted factors that should be investigated to improve our understanding of adipose–cancer cell interactions. Mol Cancer Res; 14(12); 1254–65. ©2016 AACR.
- Open Access
- 29 September 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 254
Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome?
We evaluated the prognostic significance and universal validity of the total number of evaluated lymph nodes (ELN), number of positive lymph nodes (PLN), lymph node ratio (LNR), and log odds of positive lymph nodes (LODDS) in a relatively large and homogenous cohort of surgically treated pancreatic ductal adenocarcinoma (PDAC) patients. Prospectively accrued data were retrospectively analyzed for 282 PDAC patients who had pancreaticoduodenectomy (PD) at our institution. Long-term survival was analyzed according to the ELN, PLN, LNR, and LODDS. Of these patients, 168 patients (59.5 %) had LN metastasis (N1). Mean ELN and PLN were 13.5 and 1.6, respectively. LN positivity correlated with a greater number of evaluated lymph nodes; positive lymph nodes were identified in 61.4 % of the patients with ELN ≥ 13 compared with 44.9 % of the patients with ELN < 13 (p = 0.014). Median overall survival (OS) and 5-year OS rate were higher in N0 than in N1 patients, 22.4 vs. 18.7 months and 35 vs. 11 %, respectively (p = 0.008). Mean LNR was 0.12; 91 patients (54.1 %) had LNR < 0.3. Among the N1 patients, median OS was comparable in those with LNR ≥ 0.3 vs. LNR < 0.3 (16.7 vs. 14.1 months, p = 0.950). Neither LODDS nor various ELN and PLN cutoff values provided more discriminative information within the group of N1 patients. Our data confirms that lymph node positivity strongly reflects PDAC biology and thus patient outcome. While a higher number of evaluated lymph nodes may provide a more accurate nodal staging, it does not have any prognostic value among N1 patients. Similarly, PLN, LNR, and LODDS had limited prognostic relevance.
- 29 September 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 254
Open AccessNumber of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome?
We evaluated the prognostic significance and universal validity of the total number of evaluated lymph nodes (ELN), number of positive lymph nodes (PLN), lymph node ratio (LNR), and log odds of positive lymph nodes (LODDS) in a relatively large and homogenous cohort of surgically treated pancreatic ductal adenocarcinoma (PDAC) patients. Prospectively accrued data were retrospectively analyzed for 282 PDAC patients who had pancreaticoduodenectomy (PD) at our institution. Long-term survival was analyzed according to the ELN, PLN, LNR, and LODDS. Of these patients, 168 patients (59.5 %) had LN metastasis (N1). Mean ELN and PLN were 13.5 and 1.6, respectively. LN positivity correlated with a greater number of evaluated lymph nodes; positive lymph nodes were identified in 61.4 % of the patients with ELN ≥ 13 compared with 44.9 % of the patients with ELN < 13 (p = 0.014). Median overall survival (OS) and 5-year OS rate were higher in N0 than in N1 patients, 22.4 vs. 18.7 months and 35 vs. 11 %, respectively (p = 0.008). Mean LNR was 0.12; 91 patients (54.1 %) had LNR < 0.3. Among the N1 patients, median OS was comparable in those with LNR ≥ 0.3 vs. LNR < 0.3 (16.7 vs. 14.1 months, p = 0.950). Neither LODDS nor various ELN and PLN cutoff values provided more discriminative information within the group of N1 patients. Our data confirms that lymph node positivity strongly reflects PDAC biology and thus patient outcome. While a higher number of evaluated lymph nodes may provide a more accurate nodal staging, it does not have any prognostic value among N1 patients. Similarly, PLN, LNR, and LODDS had limited prognostic relevance.
- 2 March 2013
- Published by Wiley in World Journal of Surgery
- Vol. 37 (6) , 1430-1437
Early and Late Presentations of Graft Arterial Pseudoaneurysm Following Pancreatic Transplantation
Background: Graft pseudoaneurysm (PSA) following pancreatic transplantation (PT) is a rarely reported complication that has significant morbidity and mortality. Few case reports and small series of this complication exist.Methods: Retrospective review of files of 106 patients who underwent PT at the Tel‐Aviv Sourasky Medical center between 1995 and 2010. Accessible asymptomatic patients (n = 35) were referred for graft PSA screening using ultrasound‐Doppler.Results: Eight patients developed graft PSA (8 %). All had early posttransplant sepsis. PSA incidence among patients who had perioperative sepsis is 13 %. Three patients developed early postoperative PSA, presenting as massive abdominal bleeding requiring urgent laparotomy and graft resection. Five patients were diagnosed with late‐onset graft PSA between 3 months and 11 years posttransplant: clinical presentations were massive gastrointestinal bleeding (n = 2), acute renal failure (n = 1), and asymptomatic finding on screening ultrasound‐Doppler (n = 2, 6 % of screened patients).Conclusions: PSA following PT occurs in 8 % of patients. Perioperative infection is a risk factor. Early PSAs present as massive intra‐abdominal bleeding. PSA may develop years posttransplant, may be asymptomatic, but late rupture is possible and presents as gastrointestinal bleeding. We recommend screening of patients at risk with ultrasound Doppler for early detection and treatment of asymptomatic PSAs.
- 2 March 2013
- Published by Wiley in World Journal of Surgery
- Vol. 37 (6) , 1430-1437
Early and Late Presentations of Graft Arterial Pseudoaneurysm Following Pancreatic Transplantation
Background: Graft pseudoaneurysm (PSA) following pancreatic transplantation (PT) is a rarely reported complication that has significant morbidity and mortality. Few case reports and small series of this complication exist.Methods: Retrospective review of files of 106 patients who underwent PT at the Tel‐Aviv Sourasky Medical center between 1995 and 2010. Accessible asymptomatic patients (n = 35) were referred for graft PSA screening using ultrasound‐Doppler.Results: Eight patients developed graft PSA (8 %). All had early posttransplant sepsis. PSA incidence among patients who had perioperative sepsis is 13 %. Three patients developed early postoperative PSA, presenting as massive abdominal bleeding requiring urgent laparotomy and graft resection. Five patients were diagnosed with late‐onset graft PSA between 3 months and 11 years posttransplant: clinical presentations were massive gastrointestinal bleeding (n = 2), acute renal failure (n = 1), and asymptomatic finding on screening ultrasound‐Doppler (n = 2, 6 % of screened patients).Conclusions: PSA following PT occurs in 8 % of patients. Perioperative infection is a risk factor. Early PSAs present as massive intra‐abdominal bleeding. PSA may develop years posttransplant, may be asymptomatic, but late rupture is possible and presents as gastrointestinal bleeding. We recommend screening of patients at risk with ultrasound Doppler for early detection and treatment of asymptomatic PSAs.
- 1 March 2013
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 17 (3) , 527-532
Perioperative Complications After Neoadjuvant Chemotherapy With and Without Bevacizumab for Colorectal Liver Metastases
- 1 March 2013
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 17 (3) , 527-532
Perioperative Complications After Neoadjuvant Chemotherapy With and Without Bevacizumab for Colorectal Liver Metastases
- 1 May 2011
- Vol. 13 (5) , 284-9
Cystic tumors of the pancreas: high malignant potential.
Cystic tumors of the pancreas are rare, accounting for 10% of pancreatic cysts and 1% of all pancreatic tumors; surgery is dictated by their malignant potential. To evaluate the malignancy rate of pancreatic cystic tumors and patient outcome, and to determine predictors for malignant potential. We retrospectively reviewed the medical records of patients who underwent pancreatic resection for cystic tumors between January 1996 and December 2007. The charts showed that 116 patients were operated on for a pancreatic cystic tumor; most were women (63%). The chief complaint was abdominal pain (57%). Incidental detection occurred in 27%. Preoperative workup included ultrasound, tomography, endoscopic ultrasound and fine-needle aspiration biopsy. Indications for surgery were mucinous tumor, symptomatic or enlarging cyst under surveillance, high carcinoembryonic antigen levels within the cyst, and typical manifestations of intraductal papillary mucinous tumor (IPMT). All tumors but one were resectable. Whipple operation was performed in 40%, distal pancreatectomy in 55% and total pancreatectomy in 5%. Mucinous tumors were found in 40%, of which 37T were cystadenocarcinoma and/or borderline tumor. IPMT was found in 39%; 38% of them with cancer. Other pathologies included symptomatic serous cystadenomas, neuroendocrine cystic tumors and pseudopapillary tumors. The perioperative mortality rate was 2.6%. Five-year survival rates for patients with benign vs. invasive/borderline mucinous neoplasms was 90% vs. 59%, and for non-invasive vs. invasive IPMT 89% vs. 45% respectively. Cystic tumors of the pancreas should be carefully evaluated. Surgery should be considered when a mucinous component is suspected due to the high rate of malignancy. Complete resection carries a high cure rate even in the presence of cancer.
- 1 May 2011
- Vol. 13 (5) , 284-9
Cystic tumors of the pancreas: high malignant potential.
Cystic tumors of the pancreas are rare, accounting for 10% of pancreatic cysts and 1% of all pancreatic tumors; surgery is dictated by their malignant potential. To evaluate the malignancy rate of pancreatic cystic tumors and patient outcome, and to determine predictors for malignant potential. We retrospectively reviewed the medical records of patients who underwent pancreatic resection for cystic tumors between January 1996 and December 2007. The charts showed that 116 patients were operated on for a pancreatic cystic tumor; most were women (63%). The chief complaint was abdominal pain (57%). Incidental detection occurred in 27%. Preoperative workup included ultrasound, tomography, endoscopic ultrasound and fine-needle aspiration biopsy. Indications for surgery were mucinous tumor, symptomatic or enlarging cyst under surveillance, high carcinoembryonic antigen levels within the cyst, and typical manifestations of intraductal papillary mucinous tumor (IPMT). All tumors but one were resectable. Whipple operation was performed in 40%, distal pancreatectomy in 55% and total pancreatectomy in 5%. Mucinous tumors were found in 40%, of which 37T were cystadenocarcinoma and/or borderline tumor. IPMT was found in 39%; 38% of them with cancer. Other pathologies included symptomatic serous cystadenomas, neuroendocrine cystic tumors and pseudopapillary tumors. The perioperative mortality rate was 2.6%. Five-year survival rates for patients with benign vs. invasive/borderline mucinous neoplasms was 90% vs. 59%, and for non-invasive vs. invasive IPMT 89% vs. 45% respectively. Cystic tumors of the pancreas should be carefully evaluated. Surgery should be considered when a mucinous component is suspected due to the high rate of malignancy. Complete resection carries a high cure rate even in the presence of cancer.
- 1 February 2011
- Vol. 13 (2) , 99-103
Contemporary surgical approach to hilar cholangiocarcinoma.
The diagnostic and therapeutic approach to hilar cholangiocarcinoma and thus the prognosis have changed significantly over the last two decades. Nonetheless, hilar cholangiocarcinoma presents a complex surgical challenge. To assess the outcome of the radical approach for the management of types III and IV hilar cholangiocarcinoma. We conducted a retrospective single-center study. Preoperative diagnosis was based on ultrasound, computed tomography and selective percutaneous cholangiography without tissue diagnosis. Surgery was radical and included en-bloc liver, extrahepatic biliary tree and hilar lymph nodes resection, followed by biliary reconstruction with hepaticojejunostomy. Fifteen patients (mean age 49 years, range 24-72) were managed accordingly. Anatomic classification of the biliary involvement was Bismuth-Corlette type IIIA (n=4), type IIIB (n=3) and type IV (n=8). The surgical procedures performed included four right hepatic lobectomies, five left hepatic lobectomies and six trisegmentectomies (all extended to the caudate lobe). Complete negative resection margins (RO) were accomplished in 12 cases (80%). Regional lymph node metastases were detected in five cases. There were two perioperative mortalities. Long-term follow-up (mean 30 months, range 6-72) revealed local recurrences in two cases, distant metastases in three, and both local and distant in two cases. Eleven patients are alive and 6 are without evidence of disease. The overall 2- and 5-year survival is 78% and 38% respectively. In selected patients the aggressive surgical approach to hilar cholangiocarcinoma is justified and can result in long-term survival.
- 1 February 2011
- Vol. 13 (2) , 99-103
Contemporary surgical approach to hilar cholangiocarcinoma.
The diagnostic and therapeutic approach to hilar cholangiocarcinoma and thus the prognosis have changed significantly over the last two decades. Nonetheless, hilar cholangiocarcinoma presents a complex surgical challenge. To assess the outcome of the radical approach for the management of types III and IV hilar cholangiocarcinoma. We conducted a retrospective single-center study. Preoperative diagnosis was based on ultrasound, computed tomography and selective percutaneous cholangiography without tissue diagnosis. Surgery was radical and included en-bloc liver, extrahepatic biliary tree and hilar lymph nodes resection, followed by biliary reconstruction with hepaticojejunostomy. Fifteen patients (mean age 49 years, range 24-72) were managed accordingly. Anatomic classification of the biliary involvement was Bismuth-Corlette type IIIA (n=4), type IIIB (n=3) and type IV (n=8). The surgical procedures performed included four right hepatic lobectomies, five left hepatic lobectomies and six trisegmentectomies (all extended to the caudate lobe). Complete negative resection margins (RO) were accomplished in 12 cases (80%). Regional lymph node metastases were detected in five cases. There were two perioperative mortalities. Long-term follow-up (mean 30 months, range 6-72) revealed local recurrences in two cases, distant metastases in three, and both local and distant in two cases. Eleven patients are alive and 6 are without evidence of disease. The overall 2- and 5-year survival is 78% and 38% respectively. In selected patients the aggressive surgical approach to hilar cholangiocarcinoma is justified and can result in long-term survival.